Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
738.00
-6.50 (-0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
42
43
Next >
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
April 03, 2023
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
April 03, 2023
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
April 03, 2023
Via
Benzinga
JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
March 31, 2023
Via
Benzinga
NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
March 31, 2023
Benchmark cut the price target for CuriosityStream Inc. (NASDAQ: CURI) from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in...
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For March 28
March 28, 2023
Via
Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
March 27, 2023
Via
Benzinga
Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
March 24, 2023
Via
Benzinga
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
March 23, 2023
Via
Investor Brand Network
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
March 30, 2023
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease.
Via
The Motley Fool
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
March 29, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades'
March 28, 2023
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc.
Via
Benzinga
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
March 28, 2023
From
Sonoma Biotherapeutics, Inc.
Via
Business Wire
Why Shares of Regeneron Are Rising Thursday
March 23, 2023
Regeneron released positive phase 3 trial results for its therapy Dupixent.
Via
The Motley Fool
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
March 23, 2023
Via
Benzinga
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
March 28, 2023
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
March 27, 2023
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.
Via
MarketBeat
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug
March 27, 2023
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum...
Via
Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
March 23, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023
March 27, 2023
Via
Benzinga
Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday
March 27, 2023
UBS cut the price target for DISH Network Corporation (NASDAQ: DISH) from $27 to $10. UBS analyst John Hodulik downgraded the stock from Buy to Neutral. DISH Network shares fell 2.1% to $8.57 in...
Via
Benzinga
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
March 25, 2023
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.
Via
The Motley Fool
Wall Street Has High Hopes for These 2 Nasdaq Stocks
March 24, 2023
Even in choppy markets, there are smart investments you can make.
Via
The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
March 24, 2023
The major indexes showed volatile, divergent action.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
March 24, 2023
Via
Benzinga
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
March 24, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met...
Via
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
March 24, 2023
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial...
Via
Benzinga
US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears
March 24, 2023
Renewed concerns about the banking system appear to weigh on stocks, as the major index futures point to a sharply lower opening on Friday.
Via
Benzinga
Why Are Stocks Up Today?
March 23, 2023
Stocks are up today as investors react to the latest news from the Federal Reverse concerning a new interest rate increase.
Via
InvestorPlace
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
March 23, 2023
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent.
Via
InvestorPlace
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.